Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Women – especially teen girls and young women living in sub-Saharan Africa – are disproportionately impacted by <a ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...

Gilead Sciences has bolstered its position as a leader in the HIV research space by purchasing an investigational HIV vaccine from Spanish biotech Aelix Therapeutics. The companies first linked up ...

Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two ...